Osimertinib further extends progression-free survival (PFS) over standard-of-care (SOC) first-line therapy in Asian patients with advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the phase III FLAURA* trial.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Genomic profiling of circulating tumour DNA (ctDNA) is feasible in the management of advanced non-small-cell lung cancer (NSCLC) and prompts changes in matched therapy in selected patients, a retrospective study in Hong Kong has shown.
A modified dose of XELIRI with or without bevacizumab may be an alternative second-line chemotherapy treatment for patients with metastatic colorectal cancer (CRC), according to results of the noninferiority phase III AXEPT* trial.
Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.